LiviWell raises $3.3m to seek FDA clearance and launch vaginal microbiome device
Helps maintain vaginal health after intercourse
LiviWell, a New Jersey-based women’s health company, has raised $3.3 million in an oversubscribed seed funding round to support regulatory clearance and commercial launch of its flagship product, Livi — a medical device designed to help maintain vaginal health after intercourse.
The round was led by Atlantic Venture Studio, a subsidiary of Atlantic Health System, one of New Jersey’s largest healthcare networks. LiviWell says this investment signals growing institutional interest in innovations targeting women’s sexual and reproductive health — areas that have historically received limited funding and research attention.
The new capital will be used to complete the company’s ongoing FDA clearance process and prepare for Livi’s entry into the US market.
“We are deeply grateful to our investors for believing in our vision and mission,” said Dawn Halkuff, CEO of LiviWell.
“This funding represents more than capital - it’s a validation of our team’s dedication and the potential impact Livi can have on women’s sexual health and quality of life. With this support, we’re positioned to navigate the FDA clearance process and bring Livi to the women who need it most.”
First of its kind device
Livi aims to address the common but often unspoken issues that many sexually active women experience, including vaginal odor, discharge, dripping, and discomfort - symptoms associated with vaginal pH imbalance and conditions like bacterial vaginosis.
The product, which LiviWell describes as “the first-of-its-kind post-intercourse vaginal health device”, is a medical-grade polyurethane foam device inserted intravaginally via an applicator immediately after intercourse.
It rapidly absorbs semen and other post-coital fluids in under 60 seconds, helping to maintain vaginal pH balance and support the healthy vaginal microbiome.
LiviWell says the product has been rigorously tested in clinical trials led by leading physicians in women’s pelvic health.
LiviWell submitted Livi to the FDA in June 2025 and anticipates receiving clearance in the coming months. Upon FDA clearance, Livi will be positioned as the first authorized product of its kind for post-intercourse vaginal care.
Founded in Mountain Lakes, New Jersey, LiviWell focuses on developing clinically validated technologies to address gaps in women’s intimate and sexual health. The company’s backers argue that such innovation is long overdue in an area of care where consumer needs have often been overlooked.